RAD media and Publications, page-36

Detailed Research coverage by Jones just out this morning. Interesting this coverage price target of 75c only factors in F-18 Pivalate not the rest of the pipeline.

"We base our valuation on our estimates of the market potential of this asset alone"

"With respect to the rest of the pipeline, we believe that it could represent an important source of upside for investors as assets approach and enter the clinic"

As more pipeline moves to clinic additional valuation over and above the 75c comes into play not to mention the therapeutic benefits of Pivalate are not included in the valuation. With 6 other assets there is a whole lot of newsflow to come and Pivalate de-risking that investment with a short term inflection point incoming.

Hold onto your shares as true value is realised.

Full link here - https://mcusercontent.com/2020b74e9b9a298e9cadee03b/files/fb97132f-8454-9fe8-17dc-37685dafd1e2/2023_04_18_ASX_RAD_initiation_90_.pdf